|
1）Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-8
|
|
|
|
2）Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-8
|
|
|
|
|
|
3）http: //www.haigan.gr.jp/uploads/photos/614.pdf
|
|
|
|
|
|
4）Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28: 357-60
|
|
|
|
|
|
5）Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-92
|
|
|
|
|
|
6）Maheswaran S, Sequist LV, Nagrath S. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359: 366-77
|
|
|
|
|
|
7）Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-43
|
|
|
|
|
|
8）Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011; 6: 2011-7
|
|
|
|
|
|
9）Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res. 2010; 70: 8715-25
|
|
|
|
|
|
10）Faber AC, Corcoran RB, Ebi H, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011; 1: 352-65
|
|
|
|
|
|
11）Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3: 75ra26
|
|
|
|
|
|
12）Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. J Clin Oncol. 2013; 31: 3335-41
|
|
|
|
|
|
13）Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009; 119: 3000-10
|
|
|
|
|
|
14）Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011; 17: 6298-303
|
|
|
|
|
|
15）Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14: 29-37
|
|
|
|
|
|
16）Yoshimura N, Okishio K, Mitsuoka S, et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol. 2013; 8: 96-101
|
|
|
|
|
|
17）Maruyama R, Wataya H, Seto T, et al. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. Anticancer Res. 2009; 29: 4217-21
|
|
|
|
|
|
18）Faehling M, Eckert R, Kamp T, et al. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Lung Cancer. 2013; 80: 306-12
|
|
|
|
|
|
19）Parra HS, et al. WCLC. 2011; 136: 3
|
|
|
|
|
|
20）Shukuya T, Takahashi T, Naito T, et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer. 2011; 74: 457-61
|
|
|
|
|
|
21）Asahina H, Oizumi S, Inoue A, et al. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology. 2010; 79: 423-9
|
|
|
|
|
|
22）Koizumi T, Agatsuma T, Ikegami K, et al. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib. Clin Lung Cancer. 2012; 13: 458-63
|
|
|
|
|
|
23）Oh IJ, Ban HJ, Kim KS, et al. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer. 2012; 77: 121-7
|
|
|
|
|
|
24）Hata A, Katakami N, Kaji R, et al. Erlotinib for whole-brain-radiotherapy-refractory leptomeningeal metastases after gefitinib failure in a lung adenocarcinoma patient. J Thorac Oncol. 2012; 7: 770-1
|
|
|
|
|
|
25）Sasaki S, et al. ASCO 2011（ポスター発表）
|
|
|
|
|
|
26）Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer. 2010; 68: 99-104
|
|
|
|
|
|
27）Faehling M, et al. WCLC. MO21.11
|
|
|
|
|